Medivir AB
Pharmaceutical ManufacturingView the employees at
Medivir AB-
Xiao-Xiong Zhou Director of Medicinal Chemistry at Medivir
-
Greater Stockholm Metropolitan Area
-
Rising Star
Peter Seemann Consultant Finance at Medivir AB-
Greater Stockholm Metropolitan Area
-
Rising Star
Britt-Louise Sahlberg Senior Research Scientist på Medivir AB-
Greater Stockholm Metropolitan Area
-
Top 10%
Lotta Vrang Director Bioscience på Medivir AB-
Rising Star
Caroline Beduglio Receptionist på Medivir AB-
Södertälje, Stockholm County, Sweden
-
Rising Star
Overview
Medivir develops innovative drugs with a focus on cancer where the unmet medical needs are high. The drug candidates are directed toward indication areas where available therapies are limited or missing and there are great opportunities to offer significant improvements to patients. Medivir is developing MIV-818, a pro-drug designed to selectively treat liver cancer cells and to minimize side effects. It has the potential to become the first liver-targeted, orally administered drug for patients with HCC. Collaborations and partnerships are important parts of Medivir's business model, and the drug development is conducted either by Medivir or in partnership. Birinapant, a SMAC mimetic, is exclusively outlicensed to IGM Biosciences (Nasdaq: IGMS) to be developed in combination with IGM-antibodies for the treatment of solid tumors. Medivir's share (ticker: MVIR) is listed on Nasdaq Stockholm's Small Cap list.
-